Skip to main content

Volume 3 Supplement 1


A high aminoglycoside regimen associated with renal replacement therapy for the treatment of multi-drug resistant pathogens


Infections caused by multi-drug resistant (MDR) Gram-negative (GN) organisms in critically ill patients are a therapeutic challenge. Few therapeutical options are available.


The administration of high-dose aminoglycoside (HDA) therapy coupled with high-flow continuous veno-venous hemodiafiltration (CVVHDF) could allow required high drug peaks to be achieved with reduced toxicity.


All adult patients present on the intensive care unit (ICU) between October 2009 and July 2014 who had MDR-GN sepsis were considered for HDA and high-flow (>45 mL/kg/h) CVVHDF when an isolated pathogen was at least partially sensitive to aminoglycosides and the patient's condition was not improving with conventional therapy. Optimal antibacterial activity was defined as a peak concentration of at least 8 times the minimal inhibitory concentration.


Fifteen patients infected with MDR-GN pathogens (11 with Pseudomonas aeruginosa; 10 with abdominal and 5 with respiratory infections) were treated with amikacin (n = 11), gentamicin (n = 3) or tobramycin (n = 1) and high-flow CVVHDF. A favorable clinical response was observed in 8 (53%) patients, including 3 in whom microbial eradication was obtained. Six patients were discharged alive from the ICU, and five from the hospital. No renal toxicity was observed.


In this cohort of septic patients with MDR-GN infections, HDA combined with high-flow CVVHDF represented a valuable therapeutic option. The effectiveness of this approach should be further evaluated in larger studies.

Author information

Authors and Affiliations


Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Brasseur, A., Hites, M., Roisin, S. et al. A high aminoglycoside regimen associated with renal replacement therapy for the treatment of multi-drug resistant pathogens. ICMx 3 (Suppl 1), A404 (2015).

Download citation

  • Published:

  • DOI:


  • Intensive Care Unit
  • Minimal Inhibitory Concentration
  • Gentamicin
  • Pseudomonas Aeruginosa
  • Renal Replacement Therapy